Seroprevalence of Hepatitis B virus and human immunodeficiency virus co-infection in pregnant women from Osun State, Nigeria
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.18704 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Ifeoluwa O Bejide und 10 weiteren Autor:innen. Beteiligte Einrichtung: Viral Hepatitis Research Cluster, Redeemer's University, Ede Osun State, Nigeria. Hauptthemen laut MEDLINE: Coinfection, Hepatitis B, HIV Infections, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hepatitis B virus and human immunodeficiency virus (HBV/HIV) co-infection is a global health concern due to its significant impact on morbidity and mortality. Reports of HBV/HIV co-infections are increasing in Nigeria, but information on the disease burden in pregnant women and its implications on the fetus is scarce. This study aimed to determine the prevalence of HBV/HIV co-infection in pregnant women. In addition, the study identified the risk factors for the disease in pregnant women attending antenatal clinics in Osun State, Nigeria. Methodology: We collected plasma samples from 303 consenting pregnant women and used enzyme-linked immunosorbent assay (ELISA) to test for HBV (HBsAg) and HIV I/II antigens. We obtained demographic and risk factor data on HBV and HIV transmission using a structured questionnaire.
Results
Our analysis revealed a prevalence of 3.96% for HBV/HIV co-infection in pregnant women. Bivariate analysis indicated a history of blood transfusion, oral or anal sex, and multiple sexual partners may be associated with an increased likelihood of HBV/HIV co-infection in pregnant women. After adjusting for other variables in multivariate analysis, none of these risk factors were significant at the 5% level. In contrast, formal education was a potential preventive factor in this population.
Conclusions
Our study provides valuable information on the disease burden of HBV/HIV co-infection in pregnant women in Osun State, Nigeria, highlighting the importance of routine screening for HBV and HIV during antenatal care and emphasizing the importance of implementing preventive measures to reduce the morbidity and mortality associated with HBV/HIV co-infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Hepatitis Research Cluster, Redeemer's University, Ede Osun State, Nigeria.
- Department of Biological Sciences, Redeemer's University, Ede Osun State, Nigeria.
- African Centre of Excellence for Genomics of Infectious Diseases, Redeemer's University, Ede Osun State, Nigeria.
- Department of Biological Sciences, University of Notre Dame, South Bend, IN, United States.
Zitieren
APA
Bejide, I. O., Kayode, T. A., Ebagua, A. E., Obayendo, O. D., Mere, D. O., Newman, A. B., Obi-Odunukwe, A. M., Fadare, A. K., Ahmed, M. I., Adeyemi-Kayode, T. M., & Folarin, O. A. (2024). Seroprevalence of Hepatitis B virus and human immunodeficiency virus co-infection in pregnant women from Osun State, Nigeria. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18704
Vancouver
Bejide IO, Kayode TA, Ebagua AE, Obayendo OD, Mere DO, Newman AB, et al. Seroprevalence of Hepatitis B virus and human immunodeficiency virus co-infection in pregnant women from Osun State, Nigeria. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.18704
BibTeX
@article{Bejide2024,
author = {Bejide, Ifeoluwa O and Kayode, Tolulope A and Ebagua, Angel E and Obayendo, Oghenetega D and Mere, Divine O and Newman, Abasianam B and Obi-Odunukwe, Amarachukwu M and Fadare, Ademola K and Ahmed, Muhammad I and Adeyemi-Kayode, Temitope M and Folarin, Onikepe A},
title = {Seroprevalence of Hepatitis B virus and human immunodeficiency virus co-infection in pregnant women from Osun State, Nigeria},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.18704}
}
EUVIMED